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ORIGINAL PAPER

Effects of 2 years of caloric restriction on oxidative status
assessed by urinary F2-isoprostanes: The CALERIE 2
randomized clinical trial
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William E. Kraus11 | for the CALERIE Study Investigators
1
School of Public Health, Georgia State
University, Atlanta, GA, USA
2

Department of Medicine, Washington
University School of Medicine, St Louis,
MO, USA
3
Department of Clinical and Experimental
Sciences, Brescia University School of
Medicine, Brescia, Italy
4
CEINGE Biotecnologie Avanzate, Napoli,
Italy

Summary
Calorie restriction (CR) without malnutrition slows aging in animal models. Oxidative
stress reduction was proposed to mediate CR effects. CR effect on urinary F2-isoprostanes, validated oxidative stress markers, was assessed in CALERIE, a two-year
randomized controlled trial. Healthy volunteers (n = 218) were randomized to
prescribed 25% CR (n = 143) or ad libitum control (AL, n = 75) stratifying the randomization schedule by site, sex, and BMI. F2-isoprostanes were quantified using
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LC-MS/MS in morning, fasted urine specimens at baseline, at 12 and 24 months.
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III concentration, additional measured included iPF(2a)-III, iPF2a-VI, and 8,12-iso-
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The primary measure of oxidative status was creatinine-adjusted 2,3-dinor-iPF(2a)iPF2a-VI. Intention-to-treat analyses assessed change in 2,3-dinor-iPF(2a)-III using
mixed models assessing treatment, time, and treatment-by-time interaction effects,
adjusted for blocking variables and baseline F2-isoprostane value. Exploratory analyses examined changes in iPF(2a)-III, iPF(2a)-VI, and 8,12-iso-iPF(2a)-VI. A factor
analysis used aggregate information on F2-isoprostane values. In CR group,
2,3-dinor-iPF(2a)-III concentrations were reduced from baseline by 17% and 13% at
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12 and 24 months, respectively; these changes were significantly different from AL
group (p < .01). CR reduced iPF(2a)-III concentrations by 20% and 27% at 12 and
24 months, respectively (p < .05). The effects were weaker on the VI-species. CR
caused statistically significant reduction in isoprostane factor at both time points,
and mean (se) changes were

0.36 (0.06) and

0.31 (0.06). No significant changes

in isoprostane factor were at either time point in AL group (p < .01 between-group
difference). We conclude that two-year CR intervention in healthy, nonobese men
and women reduced whole body oxidative stress as assessed by urinary concentrations of F2-isoprostanes.
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1 | INTRODUCTION

term human trials (Heilbronn et al., 2006; Sohal & Weindruch, 1996;

Caloric restriction (CR) without malnutrition is the most powerful

measure of oxidative stress, because this is a beta-oxidation metabo-

Walsh et al., 2014). 2,3-dinor-iPF(2a)-III was selected as the primary
known intervention to slow aging and protect against cancer, heart

lite of the most frequently measured isomer iPF(2a)-III (Basu, 2008;

disease, type 2 diabetes, and cognitive decline in many eukaryotic

Milne et al., 2005). Selection of 2,3-dinor-iPF(2a)-III was also based

organisms, particularly rodents and monkeys (de Cabo, Carmona-

on a theoretical concern that renal tissues may contribute dispropor-

Gutierrez, Bernier, Hall & Madeo, 2014; Fontana, Partridge & Longo,

tionally to the total production of iPF(2a)-III, whereas beta-oxidation

2010; Mattison et al., 2017). Multiple mechanisms have been

occurs predominantly in the extra-renal tissues; the measurements

hypothesized to mediate these beneficial effects of CR on aging,

of the beta-oxidation metabolites may have circumvented this prob-

including a reduction in oxidative stress (de Cabo et al., 2014; Fon-

lem. Also, urinary concentrations of 2,3-dinor-iPF(2a)-III are several

tana et al., 2010). In rodents, CR decreases markers of oxidative

fold greater as compared to its precursor iPF(2a)-III, thus reducing

stress and damage in multiple tissues (Sohal & Weindruch, 1996;

measurement error. Measurements of multiple F2-isoprostane spe-

Walsh, Shi & Van Remmen, 2014). However, there are currently no

cies provided the opportunity to assess the effect of CR intervention

data from randomized controlled trials in humans evaluating the

on an aggregate F2-isoprostane measure through factor analysis.

long-term effects of CR on reliable markers of oxidative stress.
Oxidative stress and the accumulation of oxidative injury are
deeply implicated in the pathogenesis of multiple age-associated

2 | RESULTS

chronic diseases, including heart disease, type 2 diabetes, cancer,
and neurodegeneration (Valko, Jomova, Rhodes, Kuca & Musilek,

The study design has been previously reported (Rochon et al., 2011)

2016). Urinary F2-isoprostanes generated from polyunsaturated fatty

and the main findings have been published (Ravussin et al., 2015).

acids constitute the validated index of oxidative damage in animal

As previously reported, the study population was predominantly

models, and the most reliable markers of nonenzymatic lipid peroxi-

white, and approximately 70% women (Table 1). According to the

dation in vivo in humans (Basu, 2008; Il’yasova, Scarbrough & Spaso-

enrollment criteria, mean BMI was slightly above the threshold for

jevic, 2012; Il’yasova et al., 2010; Kadiiska et al., 2005; Milne,

overweight; mean age was approximately 38 years (Table 1). At

Musiek & Morrow, 2005). High urinary F2-isoprostane concentra-

baseline, there was no difference in urinary creatinine or urinary

tions are found in patients with type 2 diabetes, hypercholes-

F2-isoprostane concentrations between the CR and AL groups.

terolemia, coronary artery disease, and obesity (Basu, 2008; Valko

We examined crude cross-sectional associations between urinary

et al., 2016). The purpose of CALERIE study—a 2-year multicenter

F2-isoprostanes and participant characteristics known to be associ-

randomized controlled trial (RCT)—was to evaluate the effects of a

ated with these biomarkers in other study populations (Table 2)

prescribed 25% CR diet in healthy, nonobese young, and middle-

(Il’yasova, Wang, et al., 2012; Kanaya et al., 2011; Keaney et al.,

aged individuals on proposed longevity biomarkers and CR-induced

2003). As expected, urinary F2-isoprostane concentrations were

metabolic adaptations. One of the targeted biomarkers was urinary

greater in women, with the least female–male difference being in

F2-isoprostanes, well-characterized and stable markers of oxidative

8,12-iso-iPF(2a)-VI (not statistically significant). Overall, F2-isopros-

stress (Zhang et al., 2010). In an animal study (Ward et al., 2005)

tane concentrations tended to be lower in African American partici-

and in a short-term intervention (Buchowski et al., 2012), F2-iso-

pants compared to Caucasians (Table 3). There was no correlation of

prostanes were reduced in response to CR. We measured urinary

urinary F2-isoprostanes with age or BMI (Table 2).

concentration of 2,3-dinor-iPF(2a)-III, as the primary indicator of

The ITT analysis of the intervention effect showed that the

oxidative status, and in addition to three F2-isoprostane isomers: iPF

reduction in 2,3-dinor-iPF(2a)-III concentrations was significantly

(2a)-III, iPF2a-VI, and 8,12-iso-iPF2a-VI. Our primary hypothesis for

greater in the CR as compared to the AL group at both time points,

this analysis—caloric restriction reduces systemic levels of oxidative

12 and 24 months (Table 3, Figure 2). Specifically, 2,3-dinor-iPF(2a)-

damage, specifically lipid peroxidation—was based on the effects of

III levels decreased at 12 months with eightfold greater change in

long-term caloric restriction in laboratory animals and/or shorter-

the CR group (p = .0001). At 24 months, 2,3-dinor-iPF(2a)-III
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significantly reduced from baseline (p = .006). CR also significantly

T A B L E 1 Demographic, anthropometric, and clinical
characteristics at baseline for the 218 participants who started the
2-year intervention
Ad libitum
(n = 75)
N (%)

3 of 9

reduced urinary concentrations of iPF(2a)-III at 12 and 24 months
(p-values .04 and .003, respectively); because this is the most fre-

Caloric restriction
(n = 143)

quently studied F2-isoprostane species, the observed effect on iPF
(2a)-III concentrations provides a reference to previously published
F2-isoprostane studies.
F2-isoprostanes are formed by nonenzymatic oxidation of arachi-

Sex
Female

53 (70.7)

99 (69.2)

donic acid, and this process produces a mix of isomers with different

Male

22 (29.3)

44 (30.8)

positions of the oxygenated carbons—the III, IV, V, and VI series
(Rokach et al., 1997). Therefore, in addition to the two F2-isopros-

Race
White

57 (76)

African
American

11 (14.7)

tanes from the III series, we measured two species from the VI ser-

111 (77.6)

ies (which are less well studied, but abundant and potentially more

15 (10.5)

sensitive markers of oxidative status (Pratico, Lawson, Rokach &

Other

7 (9.3)

FitzGerald, 2001; Dentchev, Yao, Pratico & Dunaief, 2007)). The

17 (11.9)

adjusted effects of caloric restriction on VI series species were

Mean (SD)

weaker than on III series (Table 3, Figure 1). There was no treatAge, year

37.9 (6.94)

38.0 (7.34)

ment-by-time interaction in any examined measure of F2-isopros-

BMI, kg/m2

25.1 (1.64)

25.2 (1.78)

tanes. The general pattern of changes in urinary F2-isoprostane

Creatinine, mg/ml

0.613 (0.224)

0.720 (0.350)

concentrations was similar to weight changes in the AL- and CR
groups (Figure 1).

Urinary F2-isoprostanes, ng/mg creatinine

A strong correlation between the four measured F2-isoprostane

Primary measure
2,3-dinor-iPF(2a)-III

1.90 (0.86)

species was observed. To take advantage of this intercorrelation, we

1.89 (0.81)

performed a factor analysis using all four F2-isoprostane species.

Secondary measures
iPF(2a)-III

0.211 (0.138)

0. 209 (0.124)

iPF(2a)-VI

4.05 (1.55)

4.12 (1.80)

8,12-iso-iPF(2a)-VI

5.35 (2.35)

5.43 (2.41)

First, the four F2-isoprostane variables at baseline were normalized
(mean = 0, SD = 1). The eigenvalue for the best linear combination
of the four F2-isoprostanes was 3.22, indicating that the factor
explained 80.4% of the variance in the variables; correlations were

AL, ad libitum control group; CR, 25% caloric restriction group.

0.80, 0.77, 0.92, 0.72 between the factor and the four F2-isoprostanes. That is, the summary scale contained 80.4% of the informa-

concentrations reverted to baseline in both groups: In the AL group,

tion contained in the four F2-isoprostane markers. As no additional

the concentrations were not different from baseline; in contrast, 2,3-

factor had an eigenvalue greater than 1, we chose to model a single

dinor-iPF(2a)-III

factor, called isoprostane factor. By definition, isoprostane factor

concentrations

in

the

CR

group

remained

T A B L E 2 Baseline Urinary F2-isoprostane Levels and Characteristics of CALERIE participants (n = 218)
2,3-dinor-iPF2(2a)-III
iPF(2a)-III
Mean (SD) p-value for Wilcoxon test

iPF(2a)-VI

8,12-iso-iPF(2a)-VI

Sex
Females

2.10 (0.86)

0.238 (0.139)

4.47 (1.84)

5.55 (2.57)

Males

1.41 (0.47)

0.145 (0.630)

3.25 (0.97)

5.06 (1.85)

p < .0001

p < .0001

p < .0001

p = .55

Race/ethnicity
Caucasian

1.89 (0.84)

0.215 (0.133)

4.15 (1.82)

5.58 (2.51)

African American

1.94 (0.94)

0.187 (0.132)

3.82 (1.41)

4.26 (1.29)

Other

1.86 (0.55)

0.196 (0.990)

4.04 (1.22)

5.34 (2.06)

p = .86

p = .28

p = .58

p = .02

Spearman correlation coefficient
p-value
Age

0.1125
p = .10

0.0429
p = .53

0.0360
p = .60

0.0691
p = .31

BMI

0.0365
p = .59

0.0008
p = .99

0.0125
p = .86

0.0757
p = .27
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T A B L E 3 Adjusted Changes in Urinary F2-isoprostane Levelsa at 12 and 24 Months from Baseline by Treatment Group
AL
N = 75

ng/mg creatinine

CR
N = 143

p value
AL vs. CR

P (time 3 treatment)

0.833

Primary analysis
2,3-dinor-iPF(2a)-III
Change at 12 months

0.041  0.059

0.313  0.045

.0001

Change at 24 months

0.018  0.075

0.237  0.058

.006

Exploratory analyses
iPF(2a)-III
Change at 12 months

0.012  0.012

0.042  0.009

.04

Change at 24 months

0.016  0.011

0.057  0.009

.003

Change at 12 months

0.171  0.140

0.461  0.105

.08

Change at 24 months

0.115  0.157

0.213  0.121

.09

0.486

iPF(2a)-VI
0.846

8,12-iso-iPF(2a)-VI
Change at 12 months

0.303  0.170

0.751  0.128

.058

Change at 24 months

0.381  0.184

0.663  0.141

.42

0.428

Isoprostane Factor
Change at 12 months

0.098 (0.075)

0.358 (0.057)

.004

Change at 24 months

0.048 (0.078)

0.311 (0.060)

.006

0.974

a

Adjusted for site, sex, BMI, and baseline values of F2-isoprostanes

scores had a mean = 0.0 and SD = 1 at baseline. Next, the iso-

correlated with changes in urinary 2,3-dinor-iPF(2a)-III concentration

prostane factor was defined for the two follow-up points

(rs = 0.326, p < .0001 for both groups combined; rs = 0.263,

(12 months and 24 months), using the scoring and the normalization

p = .0037 for CR group only). In contrast, change in urinary 2,3-

coefficients defined at baseline. Thus, any differences from 0 in the

dinor-iPF(2a)-III concentration was inversely correlated with change

follow-up levels of the factor should be interpreted as the propor-

in the insulin sensitivity (rs =

tion of a standard deviation value difference from the baseline mean.

combined; rs =

0.234, p = .0012 for both groups

0.193, p = .035 for CR group only).

Testing of the intervention effect (CR vs AL) on changes in the isoprostane factor was conducted similar to the primary hypothesis
(Table 3). For the AL group, there was approximately a 1/10th SD

3 | DISCUSSION

decrease in the isoprostane factor ( 0.098 SD), whereas the
decrease in the CR group was ( 0.358 SD) approximately 3.6-fold

Two years of CR in healthy, young and middle-age nonobese individ-

greater (p = .004). This relative difference between the treatment

uals resulted in a significant and persistent reduction in urinary 2,3-

groups increased to a 6.4 greater change at 24 months ( 0.048 vs.

dinor-iPF(2a)-III and iPF(2a)-III concentrations, reflecting lower accu-

0.311 SD, p = .006) (Table 3). However, we did not observe a

mulation of oxidative damage in multiple human tissues during the

treatment-by-time difference in the effect (p = .97, for the time-by-

two-year period. Urinary 2,3-dinor-iPF(2a)-III concentrations were

treatment interaction).

17% and 13% lower after 1 and 2 years of CR, respectively. This
reduction in urinary F2-isoprostane concentrations in our CR volun-

2.1 | Variables associated with F2-isoprostane
changes in the CR and AL groups

teers was associated with a CR-induced reduction in leptin and
improved insulin sensitivity.
Whether or not oxidative stress plays a role in the biology of

At baseline, urinary 2,3-dinor-iPF(2a)-III concentration was positively

aging is still unclear (Perez et al., 2009); but, multiple lines of

associated with fasting leptin (rs = 0.476, p < .0001), HMW adipo-

research indicate that oxidative stress is deeply implicated in the

(rs = 0.274,

pathogenesis of several age-related chronic diseases, including car-

p < .0001), fasting insulin (rs = 0.159, p = .019), and triiodothyronine

diovascular disease and cancer and it is considered a prevailing the-

(rs = 0.161,

sensitivity

ory of human aging (Basu, 2008; Valko et al., 2016). In particular,

nectin

(rs =

(rs = 0.342,

p < .0001),

p = .018),

and

C-reactive

inversely

with

protein
insulin

0.159, p = .019). However, in response to the intervention,

obesity is associated with increased oxidative stress, and weight loss

only changes in leptin and insulin sensitivity were significantly corre-

reduces urinary F2-isoprostane levels in obese women (Davi et al.,

lated with changes in urinary 2,3-dinor-iPF(2a)-III concentration (Fig-

2002; Duggan et al., 2016; Kanaya et al., 2011; Keaney et al., 2003).

ure 2). In particular, changes in leptin concentration were directly

To the best of our knowledge, it is not known whether CR reduces
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|

ET AL.

5 of 9

F I G U R E 1 Change in urinary F2isoprostane concentrations and in body
weight within CR and AL groups. Percent
change in each F2-isoprostane species as
compared to the baseline level: (a) 2,3dinor-iPF(2 a)-III, (b) iPF(2a)-III, (c) iPF(2 a)VI, (d) 8,12-iso-iPF(2a)-VI, (e) body weight

F I G U R E 2 Correlations between
changes in 2,3-dinor-iPF(2 a)-III and two
metabolic characteristics during the 2-year
intervention: (a) correlation with changes in
plasma leptin levels and (b) correlation with
changes in insulin sensitivity

F2-isoprostanes in men, and most importantly in nonobese individu-

F2-isoprostanes in mice, probably by increasing the production

als. In our study, we observed that CR significantly reduced multiple

of reactive intermediates such as H2O2 and hydroxyl radical

F2-isoprostane species in nonobese healthy men and women, and

through

there was a significant correlation between change in serum leptin

2003; Fortuno et al., 2010). Moreover, leptin may reduce the

and urinary 2,3-dinor-iPF(2a)-III concentrations.

activity of the cellular antioxidant paraoxonase-1 (PON-1), which

NOX

activation

(Beltowski,

Wojcicka

&

Jamroz,

It is well accepted that fat mass determines plasma leptin

in turn increases oxidative stress (Beltowski et al., 2003). Consis-

concentrations and that excessive adiposity is associated with

tent with these previously published findings, we observed a sig-

elevated circulating leptin levels (Considine et al., 1996); this plays

nificant

a key role in obesity-induced oxidative stress (Milagro, Campion &

concentration and the change in urinary 2,3-dinor-iPF(2a)-III con-

Martinez, 2006). Injection of leptin significantly increases urinary

centration.

correlation

between

the

change

in

plasma

leptin

6 of 9
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The decline of insulin resistance, a key risk factor for several

intermittent fasting, moderate protein, or essential amino acid

common cancers, may also mediate CR-related reduction in oxidative

restriction) may mimic these effects. Of note, individuals in this

stress (Longo & Fontana, 2010). Insulin resistance induced by exces-

study self-selected their CR diet. Thereby, future CR studies that

sive adiposity may increase the risk of developing cancer because of

help participants to consume foods which provide antioxidant bene-

compensatory hyperinsulinemia and increased bioavailability of IGF1

fits may realize a greater benefit on markers of oxidative stress. The

(due to reduced IGFBP-1 production), thereby up-regulating the

future implications of this work on long-term aging remain to be

PI3K/AKT pathway and stimulating cell proliferation and genomic

studied.

instability (Longo & Fontana, 2010). AKT activation inhibits the
nuclear translocation of FOXO, resulting in a downregulation of
DNA repair (i.e., DDB1) genes, and in an increase in cell proliferation
(Cyclin D) and multiple antioxidant genes, such as SOD2 and catalase
(Webb & Brunet, 2014). Accordingly, we found in this study a corre-

4 | EXPERIMENTAL PROCEDURES
4.1 | Participants and study design

lation between fasting insulin and urinary 2,3-dinor-iPF(2a)-III con-

The rationale and study design of CALERIE Phase 2 have been previ-

centration at baseline. Further, there was a significant inverse

ously described (Rochon et al., 2011). CALERIE 2 was a two-year

correlation whereby reductions in urinary 2,3-dinor-iPF(2a)-III con-

randomized controlled trial (RCT) that recruited healthy volunteers

centrations corresponded with improved insulin sensitivity.

to receive an intervention designed to either reduce energy intake

The CR diet intervention did not mandate a particular dietary

by 25% (CR group) or to maintain intake on an ad libitum basis (AL

composition. Rather participants could self-select their own diet,

group). Eligibility criteria included men 20–50 years of age (inclusive)

with dietary intake likely to vary throughout the trial in order for

and women 21–47 years of age (inclusive) and required participants

participants to remain adherent to the weight loss trajectory that

to be normal weight or slightly overweight (22.0 ≤ BMI<28.0 kg/m2)

fostered the desired level of CR. As changes in diet composition

at the screening visit. A comprehensive screening procedure identi-

were not uniform across participants, it is unlikely that dietary

fied volunteers who were healthy to participate in a two-year RCT

changes can explain the observed reduction in F2-isoprostanes.

of caloric restriction and adhere to the rigors of the study. Partici-

The strengths of this work include the RCT design, highly struc-

pants were randomized to 25% caloric restriction (CR) or ad libitum

tured and supervised 2-year CR intervention in young and middle-

control (AL) in a 2:1 ratio; randomization was stratified for site, sex

aged healthy normal weight or slightly overweight men and women,

and BMI. Study interventions: From day 1, the CR intervention tar-

and comprehensive assessments of body composition and oxidative

geted a sustained 25% restriction of energy intake prescribed on the

stress throughout the intervention. These strengths point to the

basis of the energy requirements determined from two, 2-week dou-

observed responses being related to basic biological functions and

bly labeled water measures at baseline (Rickman et al. 2011; Redman

not to those necessarily related to disease. These observations are

et al. 2014). Adherence to 25% CR was fostered by regular group

also consistent with the marked improvements in cardiometabolic

and individual meetings with trained interventionists, and a predicted

risk factors, including systolic and diastolic blood pressures, triglyc-

weight loss trajectory was used as a guide to keep participants on

erides, total cholesterol and glucose control (HOMA-IR) observed in

track. Participants randomized to the control group were advised to

the CALERIE study (Ravussin et al., 2015). The consistency of the

continue their current diets on a completely ad libitum basis. No

trends across all four F2-isoprostane species led us to the conclusion

specific level of physical activity was required or recommended for

that the overall oxidative status measured by these biomarkers can

either group. All participants received a multivitamin (Nature Made

be summarized by an integrated function, the isoprostane factor.

Multi Complete, Pharmavite LLC, Mission Hills, CA, USA) and cal-

The high correlations between the isoprostane factor and each of

cium supplement (1000 mg/d, Douglas laboratories, Pittsburgh, PA,

the F2-isoprostane species (.72 ≤ r ≤ .90) suggest that the four

USA) to foster nutritional adequacy of the self-selected diets. The

examined F2-isoprostane species reflect the biological processes are

study was approved by the institutional review boards at Pennington

closely related. However, caloric restriction induced greater changes

Biomedical Research Center, Washington University, Tufts Univer-

in the III series species, indicating that F2-isoprostane III series

sity, and Duke University. Study oversight was provided by a Data

appear to be more sensitive to CR intervention than the VI series. It

and Safety Monitoring Board and registered at ClinicalTrials.gov

could be that metabolic pathways affected by CR favor formation of

NCT00427193. Full details of the trial can be found at calerie.-

the III series F2-isoprostane isomers.

duke.edu.

In conclusion, data from this large randomized clinical trial
showed that even in young and middle-aged healthy lean or slightly
overweight men and women, sustained CR significantly reduces

4.2 | Clinical outcome assessments

oxidative stress, as reflected in lower urinary concentration of multi-

Subjects were followed throughout the course of the two-year study

ple F2-isoprostane series. More studies are needed to understand

at clinical visits at each respective study site according to a manual

the biological implications of reducing the accumulation of molecular

of procedures. Urine and blood samples were obtained during an

damage leading to age-associated chronic diseases, and whether or

inpatient stay, in the morning following an overnight fast. Samples

not other less drastic nutritional interventions in humans (e.g.,

were processed in real time and were stored frozen until assays
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were performed at the end of the study. Analytes were measured

(ITT) analyses were performed by including all available observations

at the University of Vermont Core Laboratory. Leptin (Linco

in the analysis (see CONSORT diagram, Supplemental Material). Simi-

Panel B, catalog number HADK2-61K-B), high molecular weight

lar to the impact in drug trials, in this context, use of ITT analysis is

(HMW) adiponectin (R&D ELISA, Catalog number DRP300), and

intended to generate group differences that are similar to that

high-sensitivity C-reactive protein (BNII Nephelometer, OQ1Y21,

expected in a similar population, incorporating level of compliance.

OQ1Y13) were measured using ELISA. Fasting insulin (Elecsys,

All statistical tests were conducted at a two-tailed type I error level.

Roche Diagnostics, Indianapolis, IN, USA) and triiodothyronine were

Results were generated using SAS version 9.2 and higher.

measured using a chemiluminescent immunoassay in an Immulite
analyzer. Matsuda insulin sensitivity index was a measure derived
from fasting insulin.

4.4.1 | Primary analysis
Repeated-measures analysis of covariance was applied with change

4.3 | Measurements of urinary F2-isoprostanes and
creatinine

from baseline as the dependent variable; treatment, time, and the
treatment-by-time interaction were independent variables; site, sex,
BMI stratum, and baseline values of the biomarkers were covariates.

Concentration of F2-isoprostanes in urine was adjusted for urinary

The primary hypothesis was tested by defining contrasts among the

creatinine to account for different urine diluteness between individu-

regression parameters; the predicted mean  standard error (se) are

als, which varies depending on how much liquids a person ingested

the adjusted values from this model. Type I error was controlled

and how much was reabsorbed in the kidneys (Levey et al., 2005).

using a gatekeeping strategy (Dmitrienko & Tamhane, 2007). Com-

Four isomers of F2-isoprostanes—iPF(2a)-III, 2,3-dinor-iPF(2 a)-III,

parisons were only performed at a = 0.05 if significance was

iPF(2 a)-VI, and 8,12-iso-iPF(2a)-VI—and creatinine were quantified

a = 0.05 at the higher level in the hierarchy; otherwise, Bonferroni’s

by liquid chromatography-tandem mass spectrometry (LC-MS/MS)

correction was applied by multiplying the nominal p-value by number

on Shimadzu 20A series LC and Applied Biosystems API 4000 QTrap

of tests (truncated at 1.0) (Wright, 1992).

MS/MS instruments as previously described (Il’yasova et al., 2010).
Based on creatinine measurements, the urine samples were diluted
to 0.65 mg/ml creatinine, and samples with creatinine levels equal to

4.4.2 | Exploratory analyses

or below this value were analyzed without dilution. Sample prepara-

Using methods similar to the primary hypothesis testing, the

tion included addition of internal standards [iPF(2a)-III-d4, 8,12-iso-

exploratory analyses examined associations between three F2-iso-

iPF(2a)-VI-d11, iPF(2a)-VI-d4] and 10 ll 1M HCl; washing of sam-

prostane species iPF(2a)-III, iPF(2a)-VI, and 8,12-iso-iPF(2a)-VI and

ples (500 ll) with 1 ml hexane; extraction of the analytes by ethyl

caloric restriction. We observed a strong correlation between the

acetate/hexane mixture (3/1, v/v); evaporation of the liquid; and

four individual F2-isoprostane species, indicating a redundancy in

resuspension of the residue in 150 ll of a mixture containing 70%

the information contained in the individual measures. To take sta-

mobile phase A (0.1% formic acid in water) and 30% methanol. Using

tistical advantage of this intercorrelation, we performed a factor

LC-MS/MS, 100 ll of sample was injected into two solid-core C18

analysis to define a combined variable, or factor, containing this

columns (Phenomenex Kinetex C18, 150 9 4.6 mm) in series to

common information at baseline. The advantage of a single sum-

achieve chromatographic separation of the F2-isoprostane isomers.

mary variable comprised of the information held in common by a

The mass spectrometer was operated in negative mode with the fol-

set of variables is that it is more reliable than any one single indi-

lowing MRM transitions (m/z): 353/193 [iPF(2a)-III], 357/197 [iPF

cator, and the analysis of this summary variable avoids type I error

(2a)-III-d4], 325/237 [2,3-dinor-iPF(2a)-III], 353/115 [iPF(2a)-VI and

issues inherent in the testing of multiple outcomes. This iso-

8,12-iso-iPF(2a)-VI], 364/115 [iPF(2a)-VI-d11], and 357/115 [8,12-

prostane factor was analyzed in a manner similar to the analysis of

iso-iPF(2a)-VI-d4]. Calibration samples covering the expected range

the primary hypothesis. In addition, we explored the correlations

of concentrations were prepared by adding pure material into pooled

among F2-isoprostanes, metabolic factors, and hormones known to

human urine, injected before and after the patient samples. Lower

be affected by CR: leptin, adiponectin, C-reactive protein, fasting

limits of quantification (LLOQ >80% accuracy) were 0.007, 0.34,

insulin, triiodothyronine, and insulin sensitivity (Fontana, Klein, Hol-

0.25, and 0.12 mg/ml for iPF(2a)-III, 2,3-dinor-iPF(2a)-III, iPF(2a)-VI,

loszy & Premachandra, 2006; Fontana, Meyer, Klein & Holloszy,

and 8,12-iso-iPF(2a)-VI, respectively.

2004; Fontana et al., 2010; Lecoultre, Ravussin & Redman, 2011;
Longo & Fontana, 2010).

4.4 | Statistical analyses
Baseline characteristics were compared using Wilcoxon–Mann–Whit-
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